Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
176
resultados
Última actualización
03/11/2025 [06:50:00]
Resultados 150 a 175 de 176
Resumen de: CN120019152A
The present invention provides a polynucleotide comprising a 5'untranslated region (5 '-UTR) and an open reading framework (ORF) in the 5'to 3' direction wherein the 5 '-UTR comprises at least two tandem repeat sequences 5'-GCCNCC-3 'operatively linked to the ORF, and wherein N is any nucleotide. The invention also provides a composition and a pharmaceutical composition comprising the lipid nanoparticles and the polynucleotide, and their use in medicine, in particular as a vaccine or for gene therapy.
Resumen de: EP4635518A1
The present invention provides a nanoparticle comprising a scaffold comprising a biodegradable material, an antibody, which is able to bind to a component of a Bruch's membrane, a component of a subretinal pigment epithelial deposit, or a component of an optic nerve head, and an anti-calcifying agent for use in a prophylaxis or in a treatment of age-related macular degeneration and/or optic nerve head drusen of an eye. Said prophylaxis or treatment is accomplished by the prophylaxis or the treatment of a calcified subretinal pigment epithelium deposit and/or calcified drusen of an eye. Additionally, the present invention provides a pharmaceutical composition comprising said nanoparticle and one or more pharmaceutical acceptable excipient(s). Said pharmaceutical composition is for use in a prophylaxis or in a treatment of age-related macular degeneration and/or optic nerve head drusen.
Resumen de: WO2024130236A2
Disclosed herein is an analgesic composition comprising a therapeutically effective amount of at least one endocannabinoid, at least one cannabinoid, or a combination of the endocannabinoid and cannabinoid and at least one local anesthetic; where the endocannabinoid comprises one or more endocannabinoids, one or more analogues of the endocannabinoids, one or more pharmaceutically acceptable salts of the endocannabinoid, or a combination thereof; where the cannabinoid comprises one or more cannabinoids, one or more analogues of the cannabinoids, one or more pharmaceutically acceptable salts of the cannabinoid, or a combination thereof; where at least one of the endocannabinoid or the cannabinoid is in the form of particles.
Resumen de: WO2024130106A1
A transcutaneous composition for treating an oxidative skin disorder of a mammal in need is disclosed containing an effective oxidative skin disorder treating amount of covalently-substituted oxidi zed activated charcoal (OACs) nanoparticles dissolved or dispersed in an aqueous composition containing a thickening agent providing a viscosity of about 1000 to about 20,000 cps, and about 5 to about 20 wt % of a skin permeation enhancer. A substituent of the substituted OAC comprises an average of about 2 to about 5 polyethylene glycol ( PEG) chains covalently linked to each OAC, or an average of about 2 to about 5 metal ion chelating groups covalently linked to each OAC, or an average of about 2 to about 5 PEG chains and an average of about 2 to about 5 metal ion chelating groups linked to each OAC. A method of treating an oxidative skin disorder of a mammal is also disclosed.
Resumen de: WO2024130086A1
Disclosed herein are lipid compounds and compositions comprising lipid compounds and methods of making and use thereof. The present disclosure also relates to methods for delivering an agent into a cell by introducing to the cell a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein. Also disclosed herein are methods for promoting wound repair in a subject by administering to the subject a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein.
Resumen de: WO2024129873A1
Mechanochromic impact sensors, which can further include some temperature sensing capability, are disclosed. The sensors are based on core-shell vesicles having a core and a shell material layer at least party surrounding the core. The core includes crystalline polyacetylene. The shell material layer includes silk fibroin. The sensors provide impressively large dynamic range, thereby allowing quantitative measurement of blunt force impact across a new range of forces with a single sensor.
Resumen de: EP4635939A1
The present invention relates to a novel lipid compound and a lipid nanoparticle composition comprising same. More particularly, the lipid nanoparticle composition comprises ionized lipids, helper lipids, PEG-lipids, and additives, and comprises: a novel lipid compound based on a bio-friendly vitamin; and helper lipids containing neutral lipids, and thus can alleviate changes and side effects from a delivery mechanism, and improve protein expression efficiency.
Resumen de: WO2024129826A2
In certain aspects, provided herein are therapeutic compositions comprising an mRNA formulated in a lipid nanoparticle (LNP), wherein the mRNA comprises an open reading frame encoding an HSP70 polypeptide, and methods of using the same.
Resumen de: AU2023394992A1
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Resumen de: EP4635486A2
A vaccine delivery system comprises: a hydrogel comprising a hydrophobically-modified cellulose derivative non-covalently cross-linked with a plurality of poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA) nanoparticles, wherein the hydrogel comprises about 1 wt% of the hydrophobically-modified cellulose derivative and about 5 wt% of the PEG-PLA nanoparticles; a first immunomodulatory compound encapsulated in the hydrogel, the first immunomodulatory compound comprising an immune-activating compound; and a second immunomodulatory compound encapsulated in the hydrogel, the second immunomodulatory compound comprising an antigen, wherein the hydrogel is configured to form a depot when administered to a subject.
Resumen de: WO2024079331A1
The invention relates to the field of drug delivery for inflammatory diseases, more specifically inflammatory kidney, eye, lung, and intestinal diseases, and kidney, eye, lung and intestinal diseases in general.
Resumen de: AU2023365021A1
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and/or treating RSV infections or diseases and/or symptoms caused by RSV infections by means of using the fusion protein, the nucleic acid molecule and the vaccine.
Resumen de: US2025276049A1
Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of EGFR neoepitope-encoding sequences. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.
Resumen de: US2025161221A1
Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
Resumen de: CN120390635A
The present invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent; and a preparation method thereof.
Resumen de: CN120815057A
本发明属于生物材料和生物医药领域，涉及一种包载门冬酰胺酶和二甲双胍的肿瘤细胞膜仿生碳酸钙纳米颗粒及其制备方法与应用，以PEG改性的包载二甲双胍的碳酸钙纳米颗粒为核心，同时外壳被偶联门天冬酰胺酶的肿瘤细胞膜所包裹。通过整合白血病细胞膜与CaCO3纳米颗粒构建了多功能仿生纳米系统，可在骨髓显著富集，并响应酸性微环境释放药物，有效抑制肿瘤负荷并延长生存期，为响应酸性肿瘤微环境的骨髓靶向递送平台，在白血病联合治疗中的应用潜力。
Resumen de: WO2024162304A1
The present invention addresses the problem of creating a carbamoyl lipid or a urea lipid each having a cyclic amino and developing lipid nanoparticles, and thereby providing a pharmaceutical composition for nucleic acid therapeutics and others. The present inventors have discovered a compound that is a carbamoyl lipid or a urea lipid each having a cyclic amino or a salt of the compound, and have studied on lipid nanoparticles that can be used in various pharmaceutical compositions. As a result, it was revealed that lipid nanoparticles can be formed using the compound of the present invention, which is a lipid, or a salt of the compound. By using the lipid nanoparticles containing the carbamoyl lipid or the urea lipid each having a cyclic amino according to the present invention, it is expected that a pharmaceutical composition containing the lipid nanoparticles each encapsulating a nucleic acid therein can be used as a prophylactic or therapeutic agent for astrocyte-related diseases.
Resumen de: CN120815038A
本发明提供用于治疗急性癫痫的载药蛋白复合纳米粒子及其制备方法与应用，首先，将溶于甲醇的二硬脂酰磷脂酰乙醇胺、(2,3‑二油酰基‑丙基)‑三甲基氯化铵、胆固醇、聚乙二醇接枝的二硬脂酰磷脂酰乙醇胺和化学药物RepSOX的混合溶液蒸发成膜，再制备得到阳离子载药脂质纳米粒子；然后，将3‑吲哚丙酸加热搅拌溶于去离子水中后，再加入重链铁蛋白和3‑吲哚丙酸共孵育，得到载药铁蛋白；最后，将阳离子载药脂质纳米粒子和负电荷的载药铁蛋白共同孵育，得到载药蛋白复合纳米粒子。蛋白复合纳米粒子能够有效的跨越血脑屏障，实现脑富集并修复由于癫痫发作造成的血脑屏障功能障碍，增加癫痫发作潜伏期，降低癫痫发作频率，在癫痫发作的治疗方面具有潜在应用价值。
Resumen de: CN120817866A
本发明公开了一种烷基醚脂可电离脂质化合物及其应用。一种烷基醚可电离脂质化合物，依次由头基R1、连接子L和尾部基团R2组成。本发明的烷基醚可电离脂质因采用环状碳链结构连接两个叔胺中心，递送效果显著高于线性连接两个叔胺中心结构的可电离脂质，加上烷基醚可电离脂质中含醚键的尾巴结构，提高了LNP的细胞内吞作用和细胞内涵体逃逸作用，使得更多的mRNA被递送到生物体内，并翻译表达成对应的蛋白。因此本发明的烷基醚可电离脂质对比现有技术的可电离脂质具备更好的递送效果。
Resumen de: CN120817963A
本发明涉及药物合成领域，具体是雷西莫德前药、纳米药物及其制备方法和应用。本发明提供了疏水改性活性氧响应的雷西莫德前药，实现具有超高的载药量和载药效率，有利于减少药物用量，降低毒副作用，对于临床患者预后效果具有重要意义，并且可以特异性的响应肿瘤微环境中高浓度的活性氧，最终提升实体瘤治疗的精准性与安全性。试验表明，本发明成功制备得到雷西莫德前药，其载药量最高达到了83%，载药效率＞98%；其能够特异性的响应肿瘤微环境中高浓度的活性氧，实现肿瘤治疗效果；并且其在CT26、4T1中即使在高浓度下依旧具有80%以上的细胞存活率，表明其细胞毒性低。
Resumen de: AU2024245504A1
The present invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal according to which: - a first composition/solution 1 containing an aluminum source and a source of an ion of an alkali metal M, in particular Na, is prepared; a second composition/solution 2 comprising a silicon source and a source of an ion of an alkali metal M, in particular Na, is prepared, said solutions 1 and 2 being free of any organic structuring agent; - the two compositions/solutions 1 and 2 are mixed; - the mixture is crystallized; and - said nanoparticles thus formed are optionally separated. According to the invention, said first composition/solution 1 and said second composition/solution 2 are both constituted of said source and of an alkaline phosphate buffer (PBS). The present invention also relates to the nanoparticles obtained and compositions containing them.
Resumen de: WO2024193525A1
A lipid compound for delivering a therapeutic agent, and a preparation method therefor and the use thereof. A lipid compound, which is a compound having structural formula I or a pharmaceutically acceptable form thereof. The lipid compound may be used in combination with other lipid components such as a neutral lipid, cholesterol and a polymer-bound lipid so as to form a lipid nanoparticle used for delivering a therapeutic agent (e.g., nucleic acid molecules) to achieve therapeutic or prophylactic purposes (e.g., vaccination), thereby increasing the types of ionizable lipid compounds.
Resumen de: WO2024176066A1
The present invention relates to a polymeric nanoparticle having a core@shell structure comprising poly(3-hexylthiophene) in the core and poly(3-hexylthio-phene)-S,S-dioxide in the shell with critical oxidation fraction for use in ameliorating and/or treating degenerative retinal diseases.
Resumen de: CN120815056A
本发明公开了一种口服司美格鲁肽纳米粒及其制备方法和应用，属于糖尿病治疗药物技术领域。采用本发明提供的方法，成功制备了司美格鲁肽纳米粒Sem‑PEG‑PLGA‑LMWPNPs，粒径在167～169nm之间，电位为1.13～4.89mV，载药量可达20％，测定的最高包封率为61％；制备的司美格鲁肽纳米粒Sem‑PEG‑PLGA‑LMWP NPs，对细胞毒性小，在胃肠道中的稳定性高，肠粘液穿透性好，肠道吸收能力和肠道原位吸收能力均优良，可以用作口服药物；提供的制备方法简单易操作，不使用有毒有害物质，也无有毒有害物质生成，不需要高精尖的仪器设备，适于工业推广。
Nº publicación: CN120826236A 21/10/2025
Solicitante:
国立研究开发法人科学技术振兴机构
Resumen de: WO2024181580A1
The present disclosure is lipid nanoparticles composed of a composition containing a protein selected from among an antibody and an antibody fragment, a polymer, and a lipid, and characterized in that the polymer and the protein have opposite electric charges at a predetermined pH. In the lipid nanoparticles, the protein is preferably encapsulated. Moreover, the peak top in the particle diameter distribution is preferably 80-120 nm when measuring the particle diameters of the lipid nanoparticles.
BOPI
Sede Electrónica
